Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis

被引:0
作者
E. Lau
A. Salem
J. C. N. Chan
W. Y. So
A. Kong
M. Lamotte
A. Luk
机构
[1] The Chinese University of Hong Kong,Department of Medicine and Therapeutics
[2] Prince of Wales Hospital,undefined
[3] IQVIA,undefined
[4] Real World Evidence,undefined
来源
Cost Effectiveness and Resource Allocation | / 17卷
关键词
Cost-effectiveness; Glargine U100; Neutral protamine Hagedorn (NPH); Type 2 diabetes mellitus (T2DM); CORE Diabetes Model (CDM);
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 177 条
[1]  
Holman RR(1998)Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes Lancet 352 837-853
[2]  
Turner RC(2008)Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2560-2572
[3]  
Pan CY(2008)Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2545-2559
[4]  
Sinnassamy P(1995)Insulin therapy in type II diabetes Diabetes Res Clin Pract 28 Suppl S179-84
[5]  
Chung KD(2015)Standards of medical care in diabetes - 2015 Diabetes Care 38 S1-89
[6]  
Kim KW(2007)Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients Diabetes Res Clin Pract. 76 111-118
[7]  
Quan J(2016)Diabetes incidence and prevalence in Hong Kong, China during 2006–2014 Diabet Med 34 902-908
[8]  
Li TK(2007)Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the diabetes mellitus model in patients with type 2 diabetes in Switzerland Int J Clin Pharmacol Ther 45 203-220
[9]  
Pang H(2007)Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada Pharmacoeconomics 25 253-266
[10]  
Choi CH(2004)The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making Curr Med Res Opin 20 S5-S26